1. |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1):9-29.
|
2. |
Plotti F, Sansone M, Di Donato V, et al. Quality of life and sexual function after type C2/type Ⅲ radical hysterectomy for locally advanced cervical cancer:a prospective study. J Sex Med, 2011, 8(3):894-904.
|
3. |
Lorusso D, Pietragalla A, Mainenti S, et al. Review role of topotecan in gynaecological cancers:current indications and perspectives. Crit Rev Oncol Hematol, 2010, 74(3):163-174.
|
4. |
Sugiyama T, Yakushiji M, Noda K, et al. Phase Ⅱ study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology, 2000, 58(1):31-37.
|
5. |
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Available at:http://www.cochrane-handbook.org.
|
6. |
Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies(minors):development and validation of a new instrument. ANZ J Surg, 2003, 73(9):712-716.
|
7. |
张毅, 高霞, 周玉平, 等. 伊立替康联合奈达铂治疗宫颈癌治疗的临床研究. 海南医学院学报, 2013, 19(2):232-234.
|
8. |
夏一丹, 罗军. 伊立替康与紫杉醇联合顺铂在宫颈癌新辅助化疗中的比较. 四川医学, 2013, 34(12):1805-1806.
|
9. |
李琳, 邢辉, 周敏, 等. 宫颈癌新辅助化疗119例临床分析. 中国民族民间医药, 2009, 18(8):146.
|
10. |
李琳, 周敏, 成莉, 等. 局部晚期宫颈癌患者新辅助化疗疗效观察. 临床和实验医学杂志, 2014, 13(3):208-210.
|
11. |
Xiong Y, Liang LZ, Cao LP, et al. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol, 2011, 123(1):99-104.
|
12. |
欧瑜婷. 伊立替康联合顺铂新辅助化疗治疗局部晚期宫颈癌的临床研究. 南宁:广西医科大学, 2012.
|
13. |
Bogani G, Cromi A, Serati M, et al. A prospective case-control study on the impact of neoadjuvant chemotherapy on surgery-related outcomes of laparoscopic radical hysterectomy. Anticancer Res, 2014, 34(10):5703-5708.
|
14. |
Jiang L, Yang KH, Guan QL, et al. Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer:an update meta-analysis based on randomized controlled trials. Surg Endosc, 2013, 27(7):2466-2480.
|
15. |
杜文静, 邓云丹, 代强, 等. 腹腔镜下根治性子宫切除术治疗宫颈癌的Meta分析. 中国循证医学杂志, 2014, 14(8):934-941.
|
16. |
Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev, 2012, 12:CD007406.
|
17. |
Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase Ⅲ randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, ⅡA2, and ⅡB cervical cancer:a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer, 2013, 108(10):1957-1963.
|
18. |
Yin M, Zhao F, Lou G, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer, 2011, 21(1):92-99.
|
19. |
Chen H, Liang C, Zhang L, et al. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to ⅡB) cervical cancer:randomized study. Gynecol Oncol, 2008, 110(3):308-315.
|
20. |
Minig L, Colombo N, Zanagnolo V, et al. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-ⅡB. Int J Gynecol Cancer, 2013, 23(9):1647-1654.
|
21. |
Moioli M, Papadia A, Mammoliti S, et al. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer:has this regimen still a role as neoadjuvant setting? Minerva Ginecol, 2012, 64(2):95-107.
|
22. |
Shiozawa T, Tadokoro J, Fujiki T, et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy:a postmarketing survey. Jpn J Clin Oncol, 2013, 43(5):483-491.
|
23. |
李虎, 黄鹤, 刘继红. UGT1A1基因启动子多态性与伊立替康化疗毒性作用的关系. 中华妇产科杂志, 2011, 46(12):888-891.
|